European Commission authorises rilpivirine injection in combination with cabotegravir injection to treat HIV-1 infections in adults

Approval is for rilpivirine and cabotegravir to be used together, for maintenance treatment of adults with viral load <50 copies/mL with their current antiretroviral treatment, and when the virus has not developed resistance to NNRTIs or INIs.

PharmaTimes